文献速递血栓与止血

两种重组人凝血因子Ⅷ在血友病A患者中的群体药代动力学比较

[Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

基于WAPPS-Hemo项目全球41个中心2015至2017年数据,比较拜科奇与百因止在中间型/重型血友病A患者中的群体药代动力学。拜科奇组117例、百因止组120例均为男性,拜科奇半衰期(12.3±3.5)h、TAT2%(65.2±21.7)h均优于百因止的(10.8±2.9)h和(57.0±17.9)h,且在不同年龄和剂量亚组中均占优。

要点

  • 拜科奇半衰期(12.3±3.5)h长于百因止(10.8±2.9)h。
  • 拜科奇TAT2%(65.2±21.7)h长于百因止(57.0±17.9)h。
  • 各年龄和剂量亚组中拜科奇药代参数均优于百因止。

核心结论

  • 在不同年龄组和不同注射剂量组,拜科奇的药代动力学参数均优于百因止。

研究设计与样本

  • 基于WAPPS-Hemo项目,纳入2015年1月至2017年12月全球41个血友病中心至少接受过1次拜科奇或百因止注射的中间型/重型血友病A患者。
  • 拜科奇组117例,平均年龄(27.6±17.7)岁;百因止组120例,平均年龄(23.4±16.2)岁;两组均为男性。
  • 计算两种FⅧ制剂的半衰期及FⅧ活性到达2%的时间(TAT2%),并分析不同年龄层和注射剂量下的药代动力学差异。

主要发现

  • 拜科奇组给药剂量(31.5±13.1)IU/kg,半衰期(12.3±3.5)h,TAT2%(65.2±21.7)h。
  • 百因止组给药剂量(38.17±14.83)IU/kg,半衰期(10.8±2.9)h,TAT2%(57.0±17.9)h。
  • 拜科奇组≥12岁和<12岁患者半衰期分别为(12.7±3.7)h和(11.1±2.5)h,TAT2%分别为(68.6±22.9)h和(55.8±14.6)h。
  • 百因止组≥12岁和<12岁患者半衰期分别为(11.4±3.1)h和(9.4±1.8)h,TAT2%分别为(61.1±18.0)h和(45.2±11.3)h。
  • 拜科奇组<20、20~29、30~39、≥40 IU/kg剂量组半衰期分别为(13.3±4.0)、(12.3±3.6)、(12.2±3.5)、(11.6±2.6)h,TAT2%分别为(61.5±21.4)、(63.9±22.4)、(67.0±24.3)、(68.0±19.5)h;百因止组对应半衰期分别为(11.5±3.8)、(11.4±3.7)、(11.0±2.9)、(10.4±2.3)h,TAT2%分别为(50.8±19.2)、(56.7±21.0)、(58.2±18.8)、(58.1±15.8)h。

临床怎么用

  • 可为血友病A患者选择半衰期更长、TAT2%更长的FⅧ制剂提供群体药代动力学依据。
  • 不同年龄和注射剂量下两制剂药代参数存在差异,支持个体化给药决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the differences in population pharmacokinetic (PK) parameters between two recombinant coagulation factor Ⅷ (FⅧ) preparations, Kogenate FS and Advate, in patients with hemophilia A, and to provide the theoretical basis of precise individualized treatment for those patients. Methods: Patients with moderate or severe hemophilia A who had at least one injection of Kogenate FS or Advate at 41 international hemophilia centers were enrolled as subjects from the WAPPS-Hemo project since January 2015 to December 2017. The half-lives of the two drugs and the time of FⅧ activity reaching 2% (TAT 2%) were calculated, and the differences of PK between the two drugs among different age and dose subgroups were further analyzed. Results: ①The mean age of patients in the Kogenate FS (n=117) and Advate groups (n=120) were (27.6±17.7) and (23.4±16.2) years old, respectively. All patients in the two groups were males. ②The administration doses in the Kogenate FS and Advate groups were (31.5±13.1) IU/kg and (38.17±14.83) IU/kg, respectively; the half-lives of the two drugs were (12.3±3.5) h and (10.8±2.9) h, respectively; and the TAT 2% were (65.2±21.7) h and (57.0±17.9) h, respectively. ③In the Kogenate FS group, the drug half-lives in patients aged ≥12 and <12 years old were (12.7±3.7) h and (11.1±2.5) h, respectively; the TAT 2% were (68.6±22.9) h and (55.8±14.6) h, respectively. In the Advate group, the drug half-lives in patients aged ≥12 and <12 years old were (11.4±3.1) h and (9.4±1.8) h, respectively; and the TAT 2% were (61.1±18.0) h and (45.2±11.3) h, respectively. ④In the Kogenate FS group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and ≥40 IU/kg groups were (13.3±4.0) h, (12.3±3.6) h, (12.2±3.5) h and (11.6±2.6) h, respectively; and the TAT 2% were (61.5±21.4) h, (63.9±22.4) h, (67.0±24.3) h and (68.0±19.5) h, respectively. In the Advate group, the drug half-lives in <20 IU/kg, (20-29) IU/kg, (30-39) IU/kg and <40 IU/kg groups were (11.5±3.8) h, (11.4±3.7) h, (11.0±2.9) h and (10.4±2.3) h, respectively; and the TAT 2% were (50.8±19.2) h, (56.7±21.0) h, (58.2±18.8) h and (58.1±15.8) h, respectively. Conclusion: The PK parameters of Kogenate FS are superior to those of Advate among different age and dose subgroups. 目的: 比较两种重组人凝血因子Ⅷ(FⅧ)制剂拜科奇(Kogenate(®) FS)与百因止(Advate(®))在血友病A患者中的群体药代动力学差异,以期为血友病A患者精准个体化治疗提供理论依据。 方法: 以WAPPS-Hemo项目中自2015年1月至2017年12月共纳入全球41个血友病中心至少接受过1次拜科奇或百因止注射的中间型/重型血友病A患者作为研究对象。计算两种FⅧ制剂的半衰期以及FⅧ活性到达2%的时间(TAT2%),并进一步分析不同年龄层和不同注射剂量下两种药物的药代动力学差异。 结果: ①拜科奇组117例,平均年龄为(27.6±17.7)岁;百因止组120例,平均年龄为(23.4±16.2)岁。两组患者均为男性。②拜科奇组、百因止组给药剂量分别为(31.5±13.1)IU/kg、(38.17±14.83)IU/kg,半衰期分别为(12.3±3.5)h、(10.8±2.9)h,TAT2%分别为(65.2±21.7)h、(57.0±17.9)h。③拜科奇组中≥12岁、<12岁患者的半衰期分别为(12.7±3.7)h、(11.1±2.5)h,TAT2%分别为(68.6±22.9)h、(55.8±14.6)h;百因止组中≥12岁、<12岁患者的半衰期分别为(11.4±3.1)h、(9.4±1.8)h,TAT2%分别为(61.1±18.0)h、(45.2±11.3)h。④拜科奇组中<20 IU/kg、20~29 IU/kg、30~39 IU/kg、≥40 IU/kg剂量组的半衰期分别为(13.3±4.0)h、(12.3±3.6)h、(12.2±3.5)h、(11.6±2.6)h,TAT2%分别为(61.5±21.4)h、(63.9±22.4)h、(67.0±24.3)h、(68.0±19.5)h;百因止组中<20 IU/kg、20~29 IU/kg、30~39 IU/kg、≥40 IU/kg剂量组的半衰期分别为(11.5±3.8)h、(11.4±3.7)h、(11.0±2.9)h、(10.4±2.3)h,TAT2%分别为(50.8±19.2)h、(56.7±21.0)h、(58.2±18.8)h、(58.1±15.8)h。 结论: 在不同年龄组和不同注射剂量组,拜科奇的药代动力学参数均优于百因止。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Hua BL, Chelle P, Yeung C, et al. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495135. doi:10.3760/cma.j.issn.0253-2727.2019.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。